April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Cationized Gelatine based-Nanoparticles Loaded with Modified MUC5AC Encoding Plasmid for the Treatment of Murine Experimental Dry Eye (EDE)
Yolanda Diebold; Laura Contreras-Ruiz; Giovanni K. Zorzi; Antonio López-García; Karyn F. Siemasko; Denis Hileeto; Margarita Calonge; Michael E. Stern; Begoña Seijo; Alejandro Sánchez
Author Affiliations & Notes
  • Yolanda Diebold
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Laura Contreras-Ruiz
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Giovanni K. Zorzi
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Antonio López-García
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Karyn F. Siemasko
    Biological Sciences, Allergan, Inc, Irvine, California
  • Denis Hileeto
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
  • Margarita Calonge
    Ocular Surface Group, IOBA - University of Valladolid, Valladolid, Spain
    Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Valladolid, Spain
  • Michael E. Stern
    Biological Sciences, Allergan, Inc, Irvine, California
  • Begoña Seijo
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Alejandro Sánchez
    Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Santiago de Compostela, Spain
  • Footnotes
    Commercial Relationships  Yolanda Diebold, None; Laura Contreras-Ruiz, None; Giovanni K. Zorzi, None; Antonio López-García, None; Karyn F. Siemasko, Allergan Inc., CA (USA) (F); Denis Hileeto, None; Margarita Calonge, Allergan Inc., CA (USA) (C); Michael E. Stern, Allergan Inc., CA (USA) (F); Begoña Seijo, None; Alejandro Sánchez, None
  • Footnotes
    Support  MAT2007-64626-C02-01/02 (Ministry of Science), FPU and FPI Scholarship Programs (Ministry of Education), and CIBER-BBN (Ministry of Health), Spain; Program AlBan E07D402978BR (EU)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 419. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Cationized Gelatine based-Nanoparticles Loaded with Modified MUC5AC Encoding Plasmid for the Treatment of Murine Experimental Dry Eye (EDE)
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Yolanda Diebold, Laura Contreras-Ruiz, Giovanni K. Zorzi, Antonio López-García, Karyn F. Siemasko, Denis Hileeto, Margarita Calonge, Michael E. Stern, Begoña Seijo, Alejandro Sánchez; Cationized Gelatine based-Nanoparticles Loaded with Modified MUC5AC Encoding Plasmid for the Treatment of Murine Experimental Dry Eye (EDE). Invest. Ophthalmol. Vis. Sci. 2011;52(14):419.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To achieve an efficient in vivo transfection of MUC5AC, in order to restore its levels in an inflamed ocular surface, improving the physiological parameters associated with this condition.

Methods: : Cationized gelatin and chrondroitin sulfate-based nanoparticles (NPs) were prepared by ionotropic gelation and loaded with a plasmid coding for a modified MUC5AC protein (pMUC5AC) (P201031678). EDE was induced in C57BL/6 mice with subcutaneous scopolamine and exposure to an air draft for 10 days. 5µl of naked plasmid, blank NPs, pMUC5AC-NPs or cyclosporine A (CsA) were instilled in both eyes 4 times/day for 5 days. Control animals received no instillations. Clinical signs, corneal fluorescein staining and tear production were evaluated before and after EDE induction, and after treatment. MUC5AC expression was evaluated by real time RT-PCR. Ocular structures were processed for pathology evaluation, including goblet cell (GC) count. Two-way ANOVA was done for statistical analysis.

Results: : Expression of modified MUC5AC was significantly higher in cornea and conjunctiva of pMUC5AC-NP-treated EDE animals than that of controls. Neither ocular discomfort nor irritation was observed in vivo after NP treatment. Desiccating stress significantly increased corneal fluorescein staining and decreased tear production and GC numbers. However, corneal fluorescein staining and tear production significantly improved after pMUC5AC-NP and CsA treatment. Anterior eye segment of treated mice showed normal architecture and morphology with lack of inflammatory changes.

Conclusions: : pMUC5AC-NPs were able to induce the expression of modified MUC5AC in ocular surface tissues, to improve the integrity of corneal epithelial barrier and to increase tear production and GC numbers in dry eye mice. Thus, pMUC5AC-NPs may be a potential therapy for dry eye syndrome.

Keywords: cornea: tears/tear film/dry eye • gene transfer/gene therapy • inflammation 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept